Pfizer to acquire Seagen for $43B
Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer
Seagen patent in Daiichi Sankyo ADC dispute nixed by USPTO | pharmaphorum
Pfizer to Acquire Seagen in $43 Billion Blockbuster Deal
Seagen's breast cancer therapy meets main goal in late-stage study
Pfizer buys Seagen for $43B, boosts access to cancer drugs | AP News
Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights | Reuters
Pfizer rescues biotech | Evaluate
Seattle Genetics shortens name to Seagen, dropping local connection as it goes global | Fierce Pharma
Pfizer Acquires ADC Developer Seagen in $43B Deal | Inside Precision Medicine
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
UK: SeaGen Achieves 5 GWh Milestone | Offshore Wind
Zendesk Close to Buyout Deal - Hellman & Friedman | Dow Jones
Pfizer Confirms $43B Seagen Acquisition Deal
Articles about Seagen, Inc.
Pfizer will bring Seagen's cancer drugs to the world at a scale not seen before, CEO says
Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer - Oct 12, 2021
FibroGen's Roxadustat | Ipsen's Palovarotene | Jazz Pharma's Xywav
Pfizer to acquire Seagen for $43bn to 'accelerate the next generation of cancer breakthroughs'
Frederick Cohen on LinkedIn: Nurix Announces Strategic Collaboration with Seagen Combining Industry…
2023 Pharma Choice Professional Website Gold Winner Biolumina and Seagen Inc. | PM360
Pfizer CEO 'really keen to join forces' with cancer drugmaker Seagen
Pfizer acquires Seagen for 43 billion USD - BioStock
Pfizer acquires Seagen for $43 billion
Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting
